Skip to content

Geriatric HIV Cohort in Sub Sahara Africa

Diagnosis and Treatment of Non-communicable Diseases and Geriatric Syndromes in the HIV Aging Population in Sub-Saharan Africa

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04313699
Acronym
HASA
Enrollment
500
Registered
2020-03-18
Start date
2020-07-01
Completion date
2023-06-30
Last updated
2020-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, HIV Infections, Non Communicable Diseases

Brief summary

The overall goal of the proposal is to improve capacity for detection and management of non-communicable diseases and geriatric syndromes in the aging HIV population in sub-Saharan Africa

Detailed description

The establishment and scale up of solid and sustainable HIV programs in sub-Saharan Africa (SSA) has led to a reduction in mortality and morbidity from HIV related opportunistic infections and some HIV related cancers. This improved survival has resulted in two phenomena: the first is the surfacing of non-communicable diseases (NCDs) in the HIV population, especially in those on long-term ART, and the second is increased longevity leading to increasing numbers of elderly HIV infected individuals

Interventions

The cohort will recruit HIV infected participants who are on antiretroviral treatment

Sponsors

Makerere University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Age 60 years and above * Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study. * Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

* Any clinical (physical and psychiatric) condition which prevents the patients to participate safely in the study procedures according to the judgments of a physician. * Subjects already enrolled in experimental clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Change in proportion of participants with any non communicable diseaseEnrollment, year 1, year 2Proportion with any non communicable disease (including hypertension, cardio vascular disease, respiratory disease, renal disease, non HIV related cancers, frailty)
Change in Quality of lifeEnrollment, year 1, year 2Quality of life measured using the WHO Quality of life for elderly (WHOQOL-OLD)

Secondary

MeasureTime frameDescription
Change in proportion of patients with history of fallsEnrollment, year 1, year 2Occurrence of falls measured with the History of Falls questionnaire
Change in proportion of patients with urinary incontinence measured by ICIQ-UI ShortEnrollment, year 1, year 2Presence of urinary incontinence measured with the Internal Consultation on Incontinence Questionnaire
Change in proportion of patients with polypharmacy monitoringEnrollment, year 1, year 2Polypharmacy defined as 5 or more drugs beyond antiretroviral drugs, used in the same individuals for more than 4 weeks. Information of polypharmacy will be collected by the clinic files and self reported by the participants
Change in proportion of patients with disabilityEnrollment, year 1, year 2Assessment of the Instrumental Activities of Daily Living (score 0-8, higher: better)
Change in proportion of patients with cognitive deficitEnrollment, year 1, year 2Screening using Montreal Cognitive Assessment (score 0-30; higher: better)
Change in proportion of patients with depressionEnrollment, year 1, year 2Depression measurement using the People Health Questionnaire-9 (scale 0-30, higher: worse)
Change in Nutritional status assessed by Mini Nutritional Assessments (MNA)Enrollment, year 1, year 2Nutrition screening and assessment to identify geriatric patients age who are malnourished or at risk of malnutrition.

Contacts

Primary ContactBarbara Castelnuovo, PhD
bcastelnuovo@idi.co.ug786623613
Backup ContactPhoebe Mbabazi, MMed
phibsmm@gmail.com+256704918966

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026